Clinical significance of HIF-1α expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2351-2359

  Ogawa, Kazuhiko ^a   Chiba, Itaru ^a   Morioka, Takamitsu ^b   Shimoji, Hideaki ^b   Tamaki, Wakana ^a   Takamatsu, Reika ^b   Nishimaki, Tadashi ^b   Yoshimi, Naoki ^b   Murayama, Sadayuki ^a  

^a UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Chemotherapy; Esophageal neoplasm; HIF 1 ; Radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GRANISETRON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METOCLOPRAMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960471493     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Roth JA, Putnum JB Jr, Rich TA and Forastiere AA: Cancer of the esophagus. In: Cancer: Principles and Practice of Oncology, 5th ed. Devita VT Jr, Hellman S and Rosenberg SA (eds.). Philadelphia: Lippincott-Raven, pp. 980-1021, 1997.
2. Earlam R and Cunha-Melo JR: Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67: 381-390, 1980. (Pubitemid 10059625)
3. Earlam R and Cunha-Melo JR: Oesophogeal squamous cell carcinoms: H. A critical view of radiotherapy. Br J Surg 67: 457-461, 1980.
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV and Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281: 1623-1627, 1999.
5. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167-1174, 2002. (Pubitemid 34177421)
6. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics .Trends Mol Med 8: S62-67, 2002.
7. Wenger RH and Gassmann M: Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378: 609-616, 1997.
8. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999.
9. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC and Harris AL: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53: 1192-1202, 2002. (Pubitemid 34787855)
10. Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, Tajiri T, Kudo M, Ishiwata T and Naito Z: Correlation of hypoxia inducible factor-1 alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 78: 123-130, 2005. (Pubitemid 40248793)
11. Kimura S, Kitadai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Toge T and Chayama K: Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 40: 1904-1912, 2004.
12. Enatsu S, Iwasaki A, Shirakusa T, Hamasaki M, Nabeshima K, Iwasaki H, Kuroki M and Kuroki M: Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur J Cardiothorac Surg 29: 891-895, 2006. (Pubitemid 43728579)
13. Silva P, Slevin NJ, Sloan P, Valentine H, Cresswell J, Ryder D, Price P, Homer JJ and West CM: Prognostic significance of tumor hypoxia-inducible factor-1 alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 72: 1551-1559, 2008.
14. Delias K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D, Zorn E, Holzhausen HJ and Haensgen G: Prognostic impact of HIF-I alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 184: 169-174, 2008. (Pubitemid 351365780)
15. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D and Parker C: Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9: 342-351, 2008.
16. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H and Maehara Y: Overexpression of hypoxia-inducible factor 1 alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12: 5112-5117, 2006. (Pubitemid 44453338)
17. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G and Djonov V: Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 6: R191-198, 2004.
18. Ogane N, Yasuda M, Shimizu M, Miyazawa M, Kamoshida S, Ueda A, Takata K, Sakuma Y, Miyagi Y and Kameda Y: Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol 14: 23-29, 2010.
19. Tzao C, Lee SC, Tung HJ, Hsu HS, Hsu WH, Sun GH, Yu CP, Jin JS and Cheng YL: Expression of hypoxia-inducible factor (HIF)-1 alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers 25: 141-148, 2008.
20. Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, Tanimoto T, Uenoyama M, Ozeki Y and Maehara T: Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci 96: 176-182, 2005. (Pubitemid 40575919)
21. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: Overexpression of hypoxia-inducible- factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 89: 1042-1047, 2003. (Pubitemid 37239209)
22. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
23. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14: 6264-6277, 1994.
24. Japanese Society for Esophageal Disease. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th ed. Tokyo: Kanehara Shuppan pp. 59-79, 1999.
25. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
26. Gehan E: A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrica 52: 203-224, 1965.
27. Cox DR: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
28. Gray LH, Conger AD, Ebert M, Hornsey S and Scott OC: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648, 1953.
29. Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Fukai Y, Sakurai H and Kuwano H: Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 110: 838-44, 2004 (Pubitemid 38758509)
30. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR and Overgaard J: Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83: 389-397, 2007. (Pubitemid 46907981)
31. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
32. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E and Sofras F: Evaluation of hypoxia-inducible factor 1 alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95: 425-431, 2005. (Pubitemid 40283138)